201 related articles for article (PubMed ID: 32381573)
41. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.
Koh YW; Jeon YK; Yoon DH; Suh C; Huh J
Tumour Biol; 2016 Jun; 37(6):7507-14. PubMed ID: 26678894
[TBL] [Abstract][Full Text] [Related]
42. AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features.
Rodig SJ; Ouyang J; Juszczynski P; Currie T; Law K; Neuberg DS; Rabinovich GA; Shipp MA; Kutok JL
Clin Cancer Res; 2008 Jun; 14(11):3338-44. PubMed ID: 18519761
[TBL] [Abstract][Full Text] [Related]
43. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
[TBL] [Abstract][Full Text] [Related]
44. Whole slide imaging of tumour microenvironment in classical Hodgkin's lymphoma: development of a clinical prediction model based on programmed death-ligand 1 and tumorous Reed-Sternberg cells.
Santisteban Espejo A; Bernal-Florindo I; Montero-Pavon P; Perez-Requena J; Atienza-Cuevas L; Villalba-Fernandez A; Garcia-Rojo M
J Clin Pathol; 2023 Nov; ():. PubMed ID: 37977655
[TBL] [Abstract][Full Text] [Related]
45. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
[TBL] [Abstract][Full Text] [Related]
46. Expression of CD47 antigen in Reed-Sternberg cells as a new potential biomarker for classical Hodgkin lymphoma.
López-Pereira B; Fernández-Velasco AA; Fernández-Vega I; Corte-Torres D; Quirós C; Villegas JA; Palomo P; González S; González AP; Payer Á; Bernal T; Moro-García MA; Alonso-Arias R; Alonso-Álvarez S; Colado E
Clin Transl Oncol; 2020 May; 22(5):782-785. PubMed ID: 31359339
[TBL] [Abstract][Full Text] [Related]
47. Expression of COX-2 on Reed-Sternberg cells is an independent unfavorable prognostic factor in Hodgkin lymphoma treated with ABVD.
Mestre F; Gutierrez A; Ramos R; Martinez-Serra J; Sánchez L; Matheu G; Ros T; Garcia JF; Rodriguez J
Blood; 2012 Jun; 119(25):6072-9. PubMed ID: 22547578
[TBL] [Abstract][Full Text] [Related]
48. Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy.
Fernandez-Alvarez R; Gonzalez-Rodriguez AP; Gonzalez ME; Rubio-Castro A; Dominguez-Iglesias F; Solano J; Alonso-Nogues E; Fernandez-Alvarez C; Zanabili Y; Alonso JM; Payer AR; Vicente JM; Medina J; Sancho JM
Leuk Lymphoma; 2015; 56(11):3096-102. PubMed ID: 25860241
[TBL] [Abstract][Full Text] [Related]
49. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.
Reinke S; Bröckelmann PJ; Iaccarino I; Garcia-Marquez M; Borchmann S; Jochims F; Kotrova M; Pal K; Brüggemann M; Hartmann E; Sasse S; Kobe C; Mathas S; Soekler M; Keller U; Bormann M; Zimmermann A; Richter J; Fuchs M; von Tresckow B; Borchmann P; Schlößer H; von Bergwelt-Baildon M; Rosenwald A; Engert A; Klapper W
Blood; 2020 Dec; 136(25):2851-2863. PubMed ID: 33113552
[TBL] [Abstract][Full Text] [Related]
50. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
[TBL] [Abstract][Full Text] [Related]
51. Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment.
Hsi ED
Leuk Lymphoma; 2008 Sep; 49(9):1668-80. PubMed ID: 18798102
[TBL] [Abstract][Full Text] [Related]
52. Identification of prognostic factors in classic Hodgkin lymphoma by integrating whole slide imaging and next generation sequencing.
Santisteban-Espejo A; Bernal-Florindo I; Perez-Requena J; Atienza-Cuevas L; Catalina-Fernandez I; Fernandez-Valle MDC; Romero-Garcia R; Garcia-Rojo M
Mol Omics; 2022 Dec; 18(10):1015-1028. PubMed ID: 36382626
[TBL] [Abstract][Full Text] [Related]
53. Cyclooxygenase-2 expression as a prognostic factor in pediatric classical Hodgkin lymphoma.
Elborai Y; Elgammal A; Salama A; Fawzy M; El-Desouky ED; Attia I; Shalaby LM
Clin Transl Oncol; 2020 Sep; 22(9):1539-1547. PubMed ID: 31970686
[TBL] [Abstract][Full Text] [Related]
54. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma.
Tiacci E; Döring C; Brune V; van Noesel CJ; Klapper W; Mechtersheimer G; Falini B; Küppers R; Hansmann ML
Blood; 2012 Nov; 120(23):4609-20. PubMed ID: 22955914
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
Bröckelmann PJ; Goergen H; Keller U; Meissner J; Ordemann R; Halbsguth TV; Sasse S; Sökler M; Kerkhoff A; Mathas S; Hüttmann A; Bormann M; Zimmermann A; Mettler J; Fuchs M; von Tresckow B; Baues C; Rosenwald A; Klapper W; Kobe C; Borchmann P; Engert A
JAMA Oncol; 2020 Jun; 6(6):872-880. PubMed ID: 32352505
[TBL] [Abstract][Full Text] [Related]
56. IPS-3 Validation in 1012 cases with classical hodgkin lymphoma.
Paydas S; Laçin S; Doğan M; Barista I; Yildiz B; Seydaoglu G; Karadurmus N; Civriz S; Kaplan MA; Yagci M; Gurkan E; Ercolak V
Leuk Res; 2021 Mar; 102():106519. PubMed ID: 33556744
[TBL] [Abstract][Full Text] [Related]
57. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.
Mounier N; Brice P; Bologna S; Briere J; Gaillard I; Heczko M; Gabarre J; Casasnovas O; Jaubert J; Colin P; Delmer A; Devidas A; Bachy E; Nicolas-Virelizier E; Aoudjhane A; Humbrecht C; Andre M; Carde P;
Ann Oncol; 2014 Aug; 25(8):1622-8. PubMed ID: 24827123
[TBL] [Abstract][Full Text] [Related]
58. A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG).
Eich HT; Gossmann A; Engert A; Kriz J; Bredenfeld H; Hansemann K; Skripnitchenko R; Brillant C; Pfistner B; Staar S; Diehl V; Müller RP;
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1187-92. PubMed ID: 17703895
[TBL] [Abstract][Full Text] [Related]
59. Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy.
Viviani S; Mazzocchi A; Pavoni C; Taverna F; Rossi A; Patti C; Romano A; Trentin L; Sorasio R; Guidetti A; Gottardi D; Tarella C; Cimminiello M; Zanotti R; Farina L; Ferreri AJM; Galbiati M; Corradini P; Gianni AM; Gallamini A; Rambaldi A
Hematol Oncol; 2020 Oct; 38(4):501-508. PubMed ID: 32602970
[TBL] [Abstract][Full Text] [Related]
60. Expression of TIA1 and PAX5 in Classical Hodgkin Lymphoma at Initial Diagnosis May Predict Clinical Outcome.
Nguyen TT; Frater JL; Klein J; Chen L; Bartlett NL; Foyil KV; Kreisel FH
Appl Immunohistochem Mol Morphol; 2016 Jul; 24(6):383-91. PubMed ID: 26067141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
